← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

Unicycive Therapeutics, Inc. (UNCY) 10-Year Financial Performance & Capital Metrics

UNCY •
HealthcareBiotechnologyCommercial Specialty Pharma
AboutUnicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.Show more
  • Revenue $0 -100.0%
  • EBITDA -$32M -54.7%
  • Net Income -$37M -20.2%
  • EPS (Diluted) -5.60 -337.5%
  • Gross Margin -
  • EBITDA Margin -
  • Operating Margin -
  • Net Margin -
  • ROE -2028.11%
  • ROIC -
  • Debt/Equity 0.10
  • Interest Coverage -452.35 -78.6%
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

  • ✓Momentum leader: RS Rating 81 (top 19%)
  • ✓Healthy dividend yield of 2.4%

✗Weaknesses

  • ✗Shares diluted 100.0% in last year
  • ✗Trading more than 30% below 52-week high
  • ✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-
5Y-
3Y-
TTM-

Profit (Net Income) CAGR

10Y-
5Y-
3Y-
TTM-45.26%

EPS CAGR

10Y-
5Y-
3Y-
TTM50.92%

ROCE

10Y Avg-626.45%
5Y Avg-626.45%
3Y Avg-875.4%
Latest-1527.56%

Peer Comparison

Commercial Specialty Pharma
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
ALKSAlkermes plc4.98B30.1021.05-5.25%16.37%13.28%0.01%0.04
ADMAADMA Biologics, Inc.3.71B15.5719.2265.15%42.87%48.57%2.97%0.24
UTHRUnited Therapeutics Corporation21.99B503.9018.0910.61%41.94%18.81%4.73%
PCSAProcessa Pharmaceuticals, Inc.114.71M2.17-0.56-221.71%0.04
UNCYUnicycive Therapeutics, Inc.144.49M6.93-1.24-100%-89.15%0.10
PTHSPelthos Therapeutics Inc.85.29M26.36-1.95-318.41%-40.48%
MISTMilestone Pharmaceuticals Inc.145.64M1.71-2.55-100%-282.97%4.17
AMRNAmarin Corporation plc5.74B13.80-3.45-25.51%-38.01%-18.78%0.02

Compare UNCY vs Peers

Analyze head-to-head performance against top industry competitors across valuation, growth, and profitability metrics.

vs UTHR

Compare head-to-head with United Therapeutics Corporation

vs ZLAB

Compare head-to-head with Zai Lab Limited

Compare Top 5

vs UTHR, ZLAB, AMRN, ALKS

Profit & Loss

Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Sales/Revenue+0000951K675K0
Revenue Growth %------29.02%-100%
Cost of Goods Sold+0000000
COGS % of Revenue-------
Gross Profit+0000951K675K0
Gross Margin %----100%100%-
Gross Profit Growth %------29.02%-100%
Operating Expenses+952K1.96M2.02M8.98M19M21.45M32.12M
OpEx % of Revenue----1998.21%3177.63%-
Selling, General & Admin608K1.17M1M2.9M6.57M8.55M12.1M
SG&A % of Revenue----690.54%1266.22%-
Research & Development344K795K1.01M6.08M12.44M12.9M20.01M
R&D % of Revenue----1307.68%1911.41%-
Other Operating Expenses0000000
Operating Income+-952K-1.96M-2.02M-8.98M-18.05M-20.77M-32.12M
Operating Margin %-----1898.21%-3077.63%-
Operating Income Growth %--106.2%-2.9%-344.41%-101.09%-15.08%-54.6%
EBITDA+000-8.96M-17.89M-20.49M-31.69M
EBITDA Margin %-----1881.28%-3035.56%-
EBITDA Growth %-----99.59%-14.53%-54.66%
D&A (Non-Cash Add-back)952K1.96M2.02M13K161K284K428K
EBIT-952K-2.03M-2.02M-9.39M-18.05M-30.46M-36.66M
Net Interest Income+000-628K-6K533K1.19M
Interest Income168K139K244K00615K1.26M
Interest Expense0139K244K628K6K82K71K
Other Income/Expense-168K-202K-244K-1.04M-6K-9.77M-4.61M
Pretax Income+-1.12M-2.17M-2.26M-10.02M-18.06M-30.54M-36.73M
Pretax Margin %-----1898.84%-4525.04%-
Income Tax+0000000
Effective Tax Rate %100%106.42%110.78%100%100%100%100%
Net Income+-1.12M-2.3M-2.51M-10.02M-18.06M-30.54M-36.73M
Net Margin %-----1898.84%-4525.04%-
Net Income Growth %--105.71%-8.85%-299.4%-80.27%-69.14%-20.25%
Net Income (Continuing)-1.12M-2.17M-2.26M-10.02M-18.06M-30.54M-36.73M
Discontinued Operations0000000
Minority Interest0000000
EPS (Diluted)+-0.14-0.27-0.16-8.60-1.20-1.28-5.60
EPS Growth %--92.86%40.74%-5275%86.05%-6.67%-337.5%
EPS (Basic)-0.14-0.27-0.16-8.60-1.20-1.28-5.60
Diluted Shares Outstanding794.32K847.15K1.52M1.17M1.51M2.45M6.7M
Basic Shares Outstanding794.32K842.5K1.52M1.17M1.51M2.45M6.7M
Dividend Payout Ratio-------

Balance Sheet

Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Total Current Assets+29K19K204K18.41M2.64M13.4M30.95M
Cash & Short-Term Investments25K15K016.58M455K9.7M26.14M
Cash Only25K15K016.58M455K9.7M26.14M
Short-Term Investments0000000
Accounts Receivable0000000
Days Sales Outstanding-------
Inventory0000000
Days Inventory Outstanding-------
Other Current Assets04K204K126K159K325K939K
Total Non-Current Assets+00200K333K174K792K720K
Property, Plant & Equipment000333K174K792K720K
Fixed Asset Turnover----5.47x0.85x-
Goodwill0000000
Intangible Assets0000000
Long-Term Investments0000000
Other Non-Current Assets00200K0000
Total Assets+29K19K204K18.74M2.82M14.19M31.67M
Asset Turnover----0.34x0.05x-
Asset Growth %--34.48%973.68%9088.24%-84.97%403.58%123.16%
Total Current Liabilities+1.24M903K2.88M2.1M3.28M17.53M24.12M
Accounts Payable60K322K184K742K846K821K966K
Days Payables Outstanding-------
Short-Term Debt1.05M460K2.51M29K46K18K92K
Deferred Revenue (Current)0000000
Other Current Liabilities000-29K013.13M18.94M
Current Ratio0.02x0.02x0.07x8.75x0.81x0.76x1.28x
Quick Ratio0.02x0.02x0.07x8.75x0.81x0.76x1.28x
Cash Conversion Cycle-------
Total Non-Current Liabilities+000155K0466K117K
Long-Term Debt0000000
Capital Lease Obligations000155K0466K117K
Deferred Tax Liabilities0000000
Other Non-Current Liabilities0000000
Total Liabilities1.24M903K2.88M2.26M3.28M18M24.24M
Total Debt+1.05M460K2.51M335K201K811K773K
Net Debt1.02M445K2.51M-16.24M-254K-8.89M-25.37M
Debt / Equity---0.02x--0.10x
Debt / EBITDA-------
Net Debt / EBITDA-------
Interest Coverage--14.12x-8.28x-14.29x-3008.67x-253.34x-452.35x
Total Equity+-1.21M-884K-2.67M16.48M-466K-3.81M7.43M
Equity Growth %-26.7%-202.15%717.15%-102.83%-717.38%295.09%
Book Value per Share-1.52-1.04-1.7514.12-0.31-1.551.11
Total Shareholders' Equity-1.21M-884K-2.67M16.48M-466K-3.81M7.43M
Common Stock34K8K9K15K15K35K114K
Retained Earnings-1.49M-3.66M-5.92M-15.94M-34M-64.54M-101.27M
Treasury Stock0000000
Accumulated OCI0000000
Minority Interest0000000

Cash Flow

Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Cash from Operations+-775K-1.18M-1.46M-5.77M-15.65M-18.28M-28.57M
Operating CF Margin %-----1645.74%-2708.59%-
Operating CF Growth %--51.74%-24.06%-295.27%-171.39%-16.82%-56.29%
Net Income-1.12M-2.17M-2.26M-10.02M-18.06M-30.54M-36.73M
Depreciation & Amortization00013K161K284K428K
Stock-Based Compensation024K232K966K1.05M1.77M2.35M
Deferred Taxes0000000
Other Non-Cash Items308K660K739K3.38M21K10.3M5.8M
Working Capital Changes6K305K-166K-105K1.18M-93K-427K
Change in Receivables0000000
Change in Inventory0000000
Change in Payables31K308K-68K1.24M1.27M1.28M790K
Cash from Investing+000-29K-2K-12K-72K
Capital Expenditures000-29K-2K-12K-72K
CapEx % of Revenue----0.21%1.78%-
Acquisitions0000000
Investments-------
Other Investing0000000
Cash from Financing+800K1.17M1.44M22.38M-471K27.54M45.09M
Debt Issued (Net)001.42M-15K000
Equity Issued (Net)01000K141K1000K11K1000K1000K
Dividends Paid000000-1.09M
Share Repurchases0000000
Other Financing800K0-117K119K-482K-2.65M-4.5M
Net Change in Cash25K-10K-15K16.58M-16.12M9.25M16.44M
Free Cash Flow+-775K-1.18M-1.46M-5.8M-15.65M-18.3M-28.65M
FCF Margin %-----1645.95%-2710.37%-
FCF Growth %--51.74%-24.06%-297.26%-170.07%-16.88%-56.58%
FCF per Share-0.98-1.39-0.96-4.96-10.40-7.46-4.28
FCF Conversion (FCF/Net Income)0.69x0.51x0.58x0.58x0.87x0.60x0.78x
Interest Paid0000024K0
Taxes Paid02K1K0000

Key Ratios

Metric2018201920202021202220232024
Return on Equity (ROE)----145.04%-225.47%--2028.11%
Return on Invested Capital (ROIC)----16223.49%---
Gross Margin----100%100%-
Net Margin-----1898.84%-4525.04%-
Debt / Equity---0.02x--0.10x
Interest Coverage--14.12x-8.28x-14.29x-3008.67x-253.34x-452.35x
FCF Conversion0.69x0.51x0.58x0.58x0.87x0.60x0.78x
Revenue Growth------29.02%-100%

Deep Dive Analysis

Explore detailed financial history, valuation models, and returns analysis

Valuation Overview

DCF models, peer multiples & analyst estimates

Total Return Calculator

Historical returns with dividends reinvested

Dividend History

Yield, growth, payout safety & DRIP calculator

Earnings History

EPS trends, net income & profitability analysis

Price History

Long-term charts & historical price data

Revenue History

Sales growth patterns & revenue breakdown

Financial Ratios

30 years of valuation, profitability & efficiency metrics

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.